Bladder cancer

  1. A phase 3, open-label, randomozed study of nivolumab combined with ipilimumamb versus standard of care chemotherapy in participants with previously untreated, unresectable or metastatic urotheliali cancer
    1. The purpose of the study is to assess if a combination therapy of nivolumab and ipilimumab is more effective than traditional cytostatic therapy for subjects not suited for cisplatin therapy and diagnosed with inoperable or metastatic urothelial cancer.
    Primary researcher: Petteri Hervonen

 Contact Information
tel. +358 50 427 0680